After shares climbed 36% on May 24 following the release of an American Society of Clinical Oncology abstract detailing an impressive phase II overall response rate in first-line head and neck cancer with bispecific antibody petosemtamab in combination with pembrolizumab, Merus NV is raising $400.2 million in an upsized follow-on offering.

Med-tech firms raising money in public or private financings, including: Biosig Technologies, Bruker, Medtronic.

Biopharmas raising money in public or private financings, including: Adcendo, Avelos, Cytokinetics, Expressionedits, Gameto, Insmed, Lambdavision, Matter Bio, Merus.

Med-tech firms raising money in public or private financings, including: Boryung, Lambdavision.

Biopharmas raising money in public or private financings, including: Actuate, Boost, Dyne, Enlivex, Genelux, Lucy, Reviva.

Med-tech firms raising money in public or private financings, including: Venus Concept.

Biopharmas raising money in public or private financings, including: Virios, Xgen.

Med-tech firms raising money in public or private financings, including: Royal Philips.